Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2026

Conditions
Refractory/Relapse Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L

Trial Locations (1)

Unknown

RECRUITING

Department of Hematology,920th Hospital of Joint Logistic Support Force of People's Liberation, Kunming

All Listed Sponsors
lead

Hematology department of the 920th hospital

OTHER